NASDAQ:BLU BELLUS Health (BLU) Stock Price, News & Analysis → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free BLU Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.74▼$14.7550-Day Range$14.42▼$14.7552-Week Range$6.38▼$14.76Volume3.45 million shsAverage Volume3.08 million shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BELLUS Health alerts: Email Address Ad Stansberry ResearchStrange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today. About BELLUS Health Stock (NASDAQ:BLU)BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Read More Ad Stansberry ResearchStrange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today. BLU Stock News HeadlinesMarch 21, 2024 | msn.comDeal reached between Dignity Health, Arizona Blue Cross Blue ShieldMarch 4, 2024 | msn.comThe effects of 'blue light' on human health are still unclear, says panelApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."January 4, 2024 | msn.comGlowing blue waves off Orange County coast make for thrilling start to New YearDecember 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Bluebird Bio (BLUE), United Therapeutics (UTHR)September 21, 2023 | forbes.comCBD Dosage: How Much Should You Take?June 28, 2023 | fool.comBellus Health (NASDAQ: BLU)June 27, 2023 | msn.comThese Canadian Biotech Stocks Are Quietly Changing the Face of HealthcareApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."June 25, 2023 | finance.yahoo.comBLU.TO - BELLUS Health Inc.June 17, 2023 | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)May 10, 2023 | ca.finance.yahoo.comTSX Stocks in the Healthcare Industry: Which Ones Are Worth Your Money?May 10, 2023 | finance.yahoo.comShould You Buy Bellus Health (BLU) After Golden Cross?May 2, 2023 | theglobeandmail.comClosing Bell: Bellus Health Inc up on Tuesday (BLU)April 26, 2023 | theglobeandmail.comBELLUS Health: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BLU)April 26, 2023 | finance.yahoo.comBELLUS Health Announces Meeting UpdatesApril 21, 2023 | benzinga.comMoore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law FirmApril 19, 2023 | finance.yahoo.comBellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSKApril 19, 2023 | theglobeandmail.comGSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini familyApril 19, 2023 | reuters.comGSK bets $2 bln on Bellus cough drug to soothe pipeline fearsApril 18, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)April 18, 2023 | theglobeandmail.comGSK signs deal to buy Canadian drug developer Bellus Health for US$2 billionApril 18, 2023 | finance.yahoo.comBellus Health Soars 99% As GSK Joins Buyout Bonanza With $2 Billion DealApril 18, 2023 | cnbc.comStocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and moreApril 18, 2023 | bizjournals.comGSK to buy Canadian biopharm firm Bellus Health for $2 billionApril 18, 2023 | finance.yahoo.comBellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion DealApril 18, 2023 | finance.yahoo.comWhy BELLUS Health Stock Is Rocketing Higher TodaySee More Headlines Receive BLU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BLU CUSIPN/A CIK1259942 Webwww.bellushealth.com Phone(450) 680-4500Fax45-0680-4501Employees74Year FoundedN/APrice Target and Rating Average Stock Price Target$0.00 High Stock Price Target$0.00 Low Stock Price Target$10,000,000.00 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,080,000.00 Net Margins-578,586.63% Pretax Margin-578,226.56% Return on Equity-24.27% Return on Assets-23.14% Debt Debt-to-Equity RatioN/A Current Ratio33.42 Quick Ratio33.42 Sales & Book Value Annual Sales$15,000.00 Price / Sales124,613.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book4.77Miscellaneous Outstanding Shares126,812,000Free Float96,162,000Market Cap$1.87 billion OptionableNot Optionable Beta0.19 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Roberto Francesco Bellini (Age 43)Pres, CEO & Director Comp: $790.35kMr. Ramzi Benamar (Age 50)Chief Financial Officer Comp: $650.48kDr. Andreas Orfanos FFPM (Age 64)M.B.B.Ch, MBA, Chief Operating Officer Comp: $417.58kDr. Denis Garceau Ph.D. (Age 66)Chief Scientific Officer Comp: $496.56kDr. Catherine M. Bonuccelli M.D. (Age 65)Chief Medical Officer Comp: $741.66kMr. Daniel MatthewsDirector of Investor Relations & CommunicationsMr. Tony Matzouranis (Age 50)Chief Bus. Officer Mr. Sebastien Roy (Age 47)Corp. Sec. More ExecutivesKey CompetitorsAkero TherapeuticsNASDAQ:AKROIcosavaxNASDAQ:ICVXGracell BiotechnologiesNASDAQ:GRCLCrinetics PharmaceuticalsNASDAQ:CRNXDianthus TherapeuticsNASDAQ:DNTHView All Competitors BLU Stock Analysis - Frequently Asked Questions How were BELLUS Health's earnings last quarter? BELLUS Health Inc. (NASDAQ:BLU) released its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%. What other stocks do shareholders of BELLUS Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST). This page (NASDAQ:BLU) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BELLUS Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.